摘要
目的分析甲磺酸阿帕替尼联合奥沙利铂及卡培他滨对晚期胃癌患者的近期疗效及对血清肿瘤标志物和磷脂酰肌醇3-激酶(PI3K)-蛋白激酶B(AKT)通路活性的影响。方法将南阳市中心医院2021年6月至2022年6月收治的112例晚期胃癌患者分为对照组及观察组(n=56)。对照组采取奥沙利铂联合卡培他滨治疗,观察组患者采取甲磺酸阿帕替尼联合奥沙利铂及卡培他滨的治疗方案。分析两组患者的近期疗效、血清肿瘤标志物水平、不良反应发生情况及PI3K-AKT通路活性。结果观察组患者的疾病控制率(76.79%)显著高于对照组患者(48.21%)(P<0.05)。治疗后观察组患者癌胚抗原(CEA)及糖类抗原125(CA-125)水平分别为(16.74±2.58)μg/L及(25.95±6.87)U/mL,显著低于对照组患者[(25.87±2.46)μg/L、(46.33±6.35)U/mL](P<0.05)。两组患者各不良反应发生情况相比无显著差异(P>0.05)。观察组p-PI3K及p-AKT水平在治疗后显著低于对照组患者(P<0.05)。结论甲磺酸阿帕替尼联合奥沙利铂及卡培他滨可有效降低胃癌晚期患者血清肿瘤标志物水平,抑制PI3K-AKT通路活性,控制疾病进展,且安全性良好。
Objective To analyze the short-term efficacy of Apatinib mesylate combined with oxaliplatin and capecit⁃abine on patients with advanced gastric cancer and its effects on serum tumor markers and PI3K-AKT pathway activity.Methods A total of 112 patients with advanced gastric cancer from June 2021 to June 2022 were divided into control group and observation group(n=56).Control group was treated with oxaliplatin and capecitabine,and observation group was treated with apatinib mesylate combined with oxaliplatin and capecitabine.The short-term efficacy,serum tumor marker levels,adverse reactions,and PI3K-AKT pathway activity of the two groups were analyzed.Results Thedisease control rate of observation group(76.79%)was markedly higher than that of control group(48.21%)(P<0.01).After treatment,CEA and CA-125 levels in observation group were(16.74±2.58)μg/L and(25.95±6.87)U/mL,respectively,prominently lower than those in control group[(25.87±2.46)μg/L,(46.33±6.35)U/mL](P<0.05).No statistical significance in the occurrence of adverse reactions between the two groups(P>0.05).After treatment,the levels of p-PI3K and p-AKT in observation group were dramatically lower than those in control group(P<0.05).Conclusion Apatinib mesylate combined with oxaliplatin and capecitabine could effectively reduce the level of serum tumor markers in patients with advanced gastric cancer,inhibit the activity of PI3K-AKT pathway,and control disease progression with good safety.
作者
米婷婷
MI Ting-ting(Department of Western Medicine and Pharmacy,Nanyang Central Hospital,Nanyang,Henan 473000,China)
出处
《医药论坛杂志》
2023年第20期35-39,共5页
Journal of Medical Forum
